Skip to main content
OpenTrials
Completed

NCT Number: NCT05211518

Prevention of Inflammatory Bowel Diseases in Persons at Risk The PIONIR (Preventing IBD Onset in Individuals at Risk) Trial

The goal of this study is to explore in a cross over randomized controlled trial, the ability of the Tasty&Healthy dietary intervention (NCT04239248) to alter the parameters associated with future risk of developing Chron's disease (CD) using First Degree Relatives of patients with Crohn's disease, including subjects identified in the Genetic Environmental Microbiome (GEM) Study as having a high-risk score. Specifically, the investigators aim to determine if the Tasty&Healthy dietary intervention can decrease the overall GEM Risk Score (GRS) and/or to alter the individual biological parameters that contribute to this score. The investigators hypothesize that the Tasty&Healthy dietary approach will alter the risk of CD as reflected by a decrease in the GRS.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–38 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Shaare Zedek Medical Center

Jerusalem, Israel

About this study

Several important factors associated with CD onset have already been identified in the GEM analyses, such as elevated faecal calprotectin(FC),altered gut permeability, proteomics, anti-microbial serology, and microbiome composition. These parameters are combined into the GEM Risk Score (GRS).

The first-line therapy in children with CD, according to ECCO/ESPGHAN guidelines, is exclusive enteral nutrition (EEN), meaning 8-12 weeks of exclusive liquid formula. Nutritional therapy may alter intestinal inflammation by several mechanisms, including modulation of the microbiome and an effect on intestinal permeability, both factors assessed in the GEM cohort. EEN is safe and effective, but it is challenging to implement.

Several diets, based on solid foods, have been proposed as alternatives to EEN in an attempt to increase feasibility, three of which have the most data.

Specific carbohydrate diet (SCD) restricts carbohydrates and processed foods and has been long used with variable reported effectiveness.

The CD-TREAT diet induced a positive change to the microbiome, children with active CD entered clinical remission with decreased inflammatory markers.

Crohn's Disease Exclusion Diet (CDED) is based on the exclusion of processed and pro-inflammatory foods, similar to Tasty&Healthy. A recent RCT of CDED diet with 50% liquid formula showed comparable effectiveness as EEN, including normalization of FC and positive effect on the microbiome.

However, the allowed dietary components are not liberal, and the diet is rigid, making it unsuitable as a prevention measure.

In 2014, a cook-book named "Tasty&Healthy" was published as a simple approach to dietary treatment based on the best available evidence. A steering committee of physicians experienced in IBD and nutrition, as well as leading IBD dieticians, reviewed results of dietary studies from animal models, humans and epidemiological cohorts. This review resulted in agreed-upon foods that may aggravate inflammation and thus should be excluded, including all processed and industrialized food, animal fat (dairy, meat), gluten and sugar. Overall, allowed foods in liberal quantities are those prepared at home from readily available ingredients such as fruits, vegetables, fish and shellfish, poultry, oats, eggs, non-gluten grains and legumes. Tasty&Healthy is not a specific diet; it is a dietary approach in which the allowed foods are not structured or restricted. This approach allows flexibility to increase adherence In this study, The Investigators hypothesize that the Tasty&Healthy dietary approach will alter the risk of CD as reflected by a decrease in the GEM CD risk score or alteration of its individual components.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinically healthy subjects (i.e. lack of symptoms that may suggest IBD) who are First degree relatives of someone with CD with a high faecal calprotectin (FC)>70μg/g or subjects who have a risk factor for example elevated GRS. Where available LMR will also be assessed to identify subjects ranked as top 100 at risk of CD.
  • Younger than 39 years of age, in order to maximize future risk of developing CD.
  • No overt ulcerations (other than aphthous ulcerations) in the ileum or colon. Some degree of inflammation may be seen in these high-risk subjects with increased risk parameters and this does not necessarily prompt the diagnosis of CD. Moreover, in this proof of concept study we would like to have those with the highest risk (hence some degree of initial inflammation) but without macroscopic inflammation that clearly is associated with the diagnosis of CD. Patency capsule and VCE procedure will be performed if the subjects calprotectin levels are >70μg/g.

Exclusion criteria

  • Ulcerative colitis (UC) or IBD-unclassified (IBDU) diagnosis
  • The use of antibiotics in the preceding month
  • Prior intestinal resection
  • Pregnancy (and up until six months after giving birth)
  • Celiac disease or Diabetes
  • Weight loss or weight gain by more than 20% body weight in the last 3 months
  • Extraintestinal manifestations (Arthritis/arthralgia, iritis/uveitis, skin/mouth lesions, peri-anal disease, Other fistula).
  • Underweight (children <3th BMI percentile, adult above the age of 18 years: BMI<18.5 kg/m2).

Treatment and study plan

Tasty&Healthy

Other

exclude pro-inflammatory dietary components

habitual diet

Other

subjects will continue their habitual diet.

Primary outcomes

  1. Reduction in fecal calprotectin (FC) levels over the 8 week Tasty & Healthy dietary intervention, reflecting improvement in intestinal inflammatory activity.

    Time frame: 8 weeks of Tasty&Healthy diet.

    Fecal calprotectin (FC) is a validated, sensitive marker of intestinal inflammation and reflects short term biological changes expected from the Tasty & Healthy intervention. For this reason, the primary endpoint is a reduction in FC over the 8 weeks of the intervention.

Secondary outcomes

  1. Change in the GEM integrative risk score

    Time frame: 8 weeks of Tasty & Healthy intervention

    The GEM integrative risk score assesses how a participant's composite GEM risk score changes from baseline to after the intervention. The iGRS integrates multiple biological markers to reflect overall risk for developing Crohn's disease. A reduction in the score would indicate a favorable shift in these modifiable risk factors.

  2. Change in Microbiome risk score (MRS)

    Time frame: 8 weeks of Tasty&Healthy diet.

    Decreased level of Microbiome risk score. The Microbiome risk score is a test we develop to classify individuals according to their risk to develop Crohn's disease onset.

  3. Change in Lactulose-Mannitol Ratio (LMR).

    Time frame: 8 weeks of Tasty&Healthy diet.

    Decreased level of urinary fractional excretion ratio of Lactulose to Mannitol (LMR). The LMR is an in vivo test that allow quantification of intestinal barrier permeability that is associated with risk to develop Crohn's disease.

  4. Change in Serum Metabolomics pre and post-intervention

    Time frame: 8 weeks of Tasty&Healthy diet.

    Change in levels of stool, urine, and serum metabolites. Metabolomics allow assessment of host chemical processes involving metabolites, small molecule substrates, intermediates and products of cell or microbial metabolism. Unit of measure is raw area count rescaled to set the median equal to 1.

  5. Change in Serum Proteomics pre and post-intervention

    Time frame: 8 weeks of Tasty&Healthy diet.

    Change in serum proteomics. Proteomics allows to assess initiators of most biological processes such as enzymes, cytokines, and transcription factors that contribute to Crohn's disease onset. Unit of measure is normalized protein expression.

  6. Ability to maintain a balanced diet as measured by food diaries.

    Time frame: 8 weeks of Tasty&Healthy diet.

    Will be assessed by daily caloric intake and nutritional components.

  7. Adherence with the interventions, including assessment of faecal gluten.

    Time frame: 8 weeks of Tasty&Healthy diet.

    Will be assessed using ELISA kit- Buhlman fCAL Elisa

  8. Satisfaction with the treatment received, as assessed by the Satisfaction with Food-Related Life (SFRL) questionnaire.

    Time frame: 8 weeks of Tasty&Healthy diet.

    Will be assessed by the SFRL questionnaire - Grunert KG, Dean M, Raats MM, Nielsen NA, Lumbers M; Food in Later Life Team. A measure of satisfaction with food-related life. Appetite. 2007 Sep;49(2):486-93. doi: 10.1016/j.appet.2007.03.010. Epub 2007 Mar 24. PMID: 17481776.

  9. Change in routine blood biomarkers over the course of the 8 week intervention

    Time frame: 8 weeks of Tasty&Healthy intervention

    Biomarkers will be measured at baseline, and end of each intervention in hospital laboratories.

Sponsors and collaborators

Lead sponsor

Shaare Zedek Medical Center

Other

Collaborators

  • Beilinson Hospital, Petach Tikva,Israel
  • IWK Health Centre
  • McGill University
  • Samuel Lunenfeld Research Institute, Mount Sinai Hospital
  • The Governors of the University of Alberta
  • The Hospital for Sick Children
  • University of British Columbia
  • University of Calgary
  • University of Manitoba

Registry information

Official study title

Preventing IBD Onset in Individuals at Risk

Acronym: PIONIR

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Jan 27, 2022
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.